Mankind Pharma Limited announced that its Board of Directors has approved the voluntary liquidation of its material wholly-owned subsidiary, Bharat Serums and Vaccines Limited (BSVL). This move is aimed at consolidating BSVL’s business with Mankind Pharma to drive operational efficiencies and resource utilization. BSVL’s business will be distributed to Mankind Pharma on a going concern basis, with minority shareholders in BSVL receiving cash proportionate to their stake.
Mankind Pharma Board Approves Subsidiary Liquidation
The Board of Directors of Mankind Pharma Limited has passed a resolution to initiate the voluntary liquidation process for its material wholly owned subsidiary, Bharat Serums and Vaccines Limited (BSVL). This decision, made during a board meeting on August 26, 2026, signifies a strategic move towards consolidating business operations.
Strategic Rationale and Benefits
The primary objective behind the voluntary liquidation of BSVL is to enhance operational efficiency and optimize resource utilization by integrating the businesses of both entities. The company anticipates improved organizational execution and therapy leadership through the pooling of human capital with diverse skill sets. Further efficiencies are expected in cash management, reduced compliance burdens, strengthened governance, and rationalized expenses. The integration aims to consolidate material business within the parent company, Mankind Pharma.
Business Distribution and Shareholder Impact
Following the liquidation, the business of BSVL will be distributed to Mankind Pharma, which holds 96% of BSVL’s shares, on a going concern basis. This distribution will occur immediately after receiving necessary approvals and requisite documents. The remaining 4% shareholding in BSVL, held by Appian Properties Private Limited (a wholly owned subsidiary of Mankind Pharma), will be settled with cash proportionate to its shareholding. This value will be determined based on a valuation report from an independent valuer.
Liquidation Process and Compliance
The voluntary liquidation of BSVL will be managed by a liquidator appointed by BSVL. The process will adhere to the provisions of the Insolvency and Bankruptcy Code, 2016, and the Insolvency and Bankruptcy Board of India (Voluntary Liquidation Process) Regulations, 2017, along with other applicable laws.
Shareholding Pattern Unchanged
The announcement clarifies that there will be no change in the shareholding pattern of Mankind Pharma Limited as a result of this voluntary liquidation. However, BSVL itself will be dissolved, and the shares held by Mankind Pharma and Appian will stand cancelled.
Source: BSE
